MARKET

BNGOW

BNGOW

Bionano Genomics
NASDAQ
0.2900
0.0000
0.00%
Closed 16:00 01/27 EST
OPEN
0.2900
PREV CLOSE
0.2900
HIGH
0.2900
LOW
0.2900
VOLUME
0
TURNOVER
306
52 WEEK HIGH
1.080
52 WEEK LOW
0.0401
MARKET CAP
--
P/E (TTM)
-0.7099
1D
5D
1M
3M
1Y
5Y
BRIEF-Bionano Announces Launch Of Next-Generation Versions Of Its Reagent Kits And Chip Consumable, Along With Updates To Its Instrument Control And Bionano Access Software
Reuters · 5d ago
BRIEF-Bionano Announces Publication Of Interim Readout From Trial Analyzing Optical Genome Mapping As Potential Standard Of Care For Prenatal Testing
Reuters · 01/18 17:52
BRIEF-Bionano with NVIDIA To Accelerate Data Processing Solution For Optical Genome Mapping Workflow
Reuters · 01/12 13:42
BRIEF-Bionano Genomics Reports Q4 Revenue Of $7.9 Mln
Reuters · 01/05 13:55
BRIEF-Bionano Genomics To Acquire Purigen Biosystems
Reuters · 11/28/2022 22:04
Publication Shows Utility of OGM in Solid Tumor Research with Study on Detection of Complex Genomic Rearrangements in Prostate Cancer
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study utilizing optical genome mapping (OGM) to detect structural variants (SVs) and balanced rearrangements relevant to prostate cancer...
GlobeNewswire · 11/21/2022 13:00
Bionano Genomics Reports Third Quarter 2022 Financial Results and Highlights Recent Business Progress
– 55% year-over-year revenue growth in Q3 2022 – On track to achieve all 2022 ELEVATE! milestones – Strong balance sheet with $180.2 million in cash, cash equivalents, and available-for-sale securities at the end of Q3 2022 – Conference call today, Novembe...
GlobeNewswire · 11/03/2022 20:01
Publication Recommends OGM for Analysis of Hematological Neoplasms Due to Streamlined Structural Variant Detection and High Concordance with Traditional Cytogenetic Methods
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the first published validation study to evaluate the performance of optical genome mapping (OGM) versus traditional cytogenetic techniques for the analysis o...
GlobeNewswire · 11/03/2022 12:00
More
About BNGOW
Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

Webull offers kinds of BioNano Genomics Inc stock information, including NASDAQ:BNGOW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNGOW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNGOW stock methods without spending real money on the virtual paper trading platform.